Background: Congenital adrenal hyperplasia arising from 21-hydroxylase deficiency is associated with mutations in the CYP21 gene on chromosome 6p. This is the first report on the mutational spectrum of the CYP21 gene in Singapore. Methods: To catalogue the mutations, ten exons of the CYP21 gene from 28 Singaporean patients were analyzed by PCR amplification and direct sequencing. Results: Common mutations in descending order were the intron 2 splice site mutation (32.7% of the alleles), the I172N mutation (23.1% of the alleles), and the R356W mutation (19.2% of the alleles). Two potentially novel mutations were discovered: (1) duplication of 111 bp from codon 21 to codon 57 (exon 1) and (2) missense mutation (L261P, exon 7). There was generally a good genotype-phenotype correlation, allowing accurate prediction of the disease severity.

White PC, New MI, Dupont B: Congenital adrenal hyperplasia. N Engl J Med 1987;316:1519–1554.
Young MC, Hughes IA: Congenital adrenal hyperplasia; in Grossman A (ed): Clinical Endocrinology. Oxford, Blackwell, 1998, pp 450–473.
Higashi Y, Yoshioka H, Yamane M, Gotoh O, Fujii Kuriyama YF: Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: A pseudogene and a genuine gene. Proc Natl Acad Sci USA 1986;83:2841–2845.
White PC, New MI, Dupont B: Structure of the human steroid 21-hydroxylase genes. Proc Natl Acad Sci USA 1986;83:5111–5115.
New MI: 21-hydroxylase deficiency congenital adrenal hyperplasia. J Steroid Biochem Mol Biol 1994;48:15–22.
Forrest MG, David M, Morel Y: Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J Steroid Biochem Mol Biol 1993;45:75–82.
Miller WL, Levine LS: Molecular and clinical advances in congenital adrenal hyperplasia. J Pediatr 1987;111:1–17.
Wedell A, Ritzen EM, Stengler BH, Luthman H: Steroid 21-hydroxylase deficiency: Three additional mutated alleles and establishment of phenotype-genotype relationships of common mutations. Proc Natl Acad Sci USA 1992;89:7232–7236.
Speiser PW, Dupont B, Zhu D, Serrat J, Buegeleisen M, Tusie-Luna MT, Lesser M, New MI, White PC: Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992;90:584–595.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual, ed 2. New York, Cold Spring Harbor Laboratory Press, 1989.
Rodrigues NR, Dunham I, Yu CY Carroll MC, Porter RR, Campbell RD: Molecular characterization of the HLA-linked steroid 21-hydroxylase-B gene from an individual with congenital adrenal hyperplasia. EMBO J 1987;6:1653–1661.
Owerbach D, Crawford YM, Draznin MB: Direct analysis of CYP21B genes in 21-hydroxylase deficiency using polymerase chain reaction amplification. Mol Endocrinol 1990;4:125–131.
Wilson RC, Mercado AB, Cheng KC, New MI: Steroid 21-hydroxylase deficiency: Genotype may not predict phenotype. J Clin Endocrinol Metab 1995;80:2322–2329.
Wedell A: Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): Implications for diagnosis, prognosis and treatment. Acta Paediatr 1998;87:159–164.
Ferenczi A, Garami M, Kiss E, Pek M, Sasvari-Szekely M, Barta C, Staub M, Solyom J, Fekete G: Screening for mutations of 21-hydroxylase gene in Hungarian patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999;84:2369–2372.
Lee HH, Chao HT, Lee YJ, Shu SG, Chao MC, Kuo JM, Chung BC: Identification of four novel mutations in the CYP21 gene in congenital adrenal hyperplasia in the Chinese. Hum Genet 1998;103:304–310.
Speiser PW, White P: Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Clin Endocrinol 1998;49:411–417.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.